Latest filings (excl ownership)
REVOKED
Registration or securities revoked
26 Aug 19
8-K
Entry into a Material Definitive Agreement
28 Sep 12
8-K
Entry into a Material Definitive Agreement
7 Sep 12
8-K
Entry into a Material Definitive Agreement
26 Jul 12
10-K
2011 FY
Annual report
12 Jul 12
8-K
Departure of Directors or Certain Officers
6 Jul 12
8-K
Other Events
3 Jul 12
10-Q
2011 Q3
Quarterly report
23 Apr 12
NT 10-K
Notice of late annual filing
30 Mar 12
8-K
Other Events
6 Mar 12
8-K
Departure of Directors or Certain Officers
6 Feb 12
8-K
Other Events
12 Jan 12
8-K/A
Departure of Directors or Certain Officers
12 Jan 12
NT 10-Q
Notice of late quarterly filing
15 Nov 11
10-Q
2011 Q2
Quarterly report
15 Aug 11
8-K/A
Submission of Matters to a Vote of Security Holders
29 Jun 11
8-K
Departure of Directors or Certain Officers
23 Jun 11
8-K
Departure of Directors or Certain Officers
2 Jun 11
10-Q
2011 Q1
Quarterly report
16 May 11
DEF 14A
Definitive proxy
2 May 11
10-K
2010 FY
Annual report
31 Mar 11
8-K
Departure of Directors or Certain Officers
15 Feb 11
8-K
Bringing Total Award to Over $730,000
5 Jan 11
8-K
Entry into a Material Definitive Agreement
22 Dec 10
8-K
Entry into a Material Definitive Agreement
8 Dec 10
CT ORDER
Confidential treatment order
8 Dec 10
10-Q
2010 Q3
Quarterly report
15 Nov 10
8-K
Neogenix Oncology® Receives FDA Orphan Drug Status for Ensituximab (NPC-1C) for Treatment of Pancreatic Cancer
1 Nov 10
D
$40M in equity, sold $846.23K, 16 investors
8 Oct 10
8-K
Other Events
7 Oct 10
8-K
Other Events
30 Sep 10
8-K
Other Events
23 Sep 10
8-K
Entry into a Material Definitive Agreement
3 Sep 10
10-Q
2010 Q2
Quarterly report
12 Aug 10
CT ORDER
Confidential treatment order
3 Aug 10
UPLOAD
Letter from SEC
3 Aug 10
CORRESP
Correspondence with SEC
29 Jul 10
10-12G/A
Registration of securities (amended)
16 Jul 10
UPLOAD
Letter from SEC
7 Jul 10
10-12G/A
Registration of securities (amended)
30 Jun 10
Latest ownership filings
No filings